1. DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's disease. (15th January 2020) Authors: Plevris, N; Fulforth, J; Jenkinson, P; Lyons, M; Chuah, C; Siakavellas, S; Pattenden, R; Arnott, I; Jones, G; Lees, C Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PTH-062 The utility of serum calprotectin as a biomarker in predicting inflammatory bowel disease. (22nd June 2015) Authors: Kalla, R; Kennedy, NA; Ventham, NT; Visconti, M; Adams, A; Jarvie, A; Pattenden, R; Satsangi, J Journal: Gut Issue: Volume 64(2015)Supplement 1 Page Start: A433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PWE-025 Serum Calprotectin – A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. (17th August 2016) Authors: Kalla, R; Kennedy, NA; Ventham, NT; Boyapati, R; Adams, AT; Nimmo, E; Visconti, M; Drummond, H; Ho, GT; Pattenden, R; Wilson, DC; Satsangi, J Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗